PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
David F. McDermott, MD - Redefining the Management of Advanced RCC: An Expert Tumor Board on Rational Selection, Sequencing, and Combination of Targeted Agents and Immunotherapy
Go online to PeerView.com/FPP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, recorded from a live event at the 2019 American Society of Clinical Oncology Annual Meeting, a panel of kidney cancer experts offers case-centric discussion of key evidence that supports clinical decision-making through multiple lines of therapy in advanced RCC, as well as practical instruction on how to effectively and safely integrate novel targeted and immunotherapeutic strategies in an increasingly complex RCC treatment landscape. Upon completion of this activity, participants should be better able to: Summarize the latest evidence and ongoing investigations with novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies, in advanced renal cell carcinoma (RCC), Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment, Recommend targeted agents and immune checkpoint inhibitors optimally to patients with pretreated advanced RCC through multiple lines of therapy, with considerations of prior treatment history and patient comorbidities, Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC.